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ABSTRACT
Here we aim to present an accessible review of
the pharmacological targets for pain manage-
ment, and succinctly discuss the newest trends
in pain therapy. A key task for current pain
pharmacotherapy is the identification of recep-
tors and channels orchestrating nociception.
Notwithstanding peripheral alterations in the
receptors and channels following pathophysio-
logical events, the modulatory mechanisms in
the central nervous system are also fundamen-
tal to the regulation of pain perception. Bridg-
ing preclinical and clinical studies of peripheral
and central components of pain modulation,
we present the different types of pain and relate
these to pharmacological interventions. We
firstly highlight the roles of several peripheral
nociceptors, such as NGF, CGRP, sodium
channels, and TRP-family channels that may
become novel targets for therapies. In the cen-
tral nervous system, the roles of calcium chan-
nels and gabapentinoids as well as NMDA
receptors in generating excitability are covered
including ideas on central sensitization. We
then turn to central modulatory systems and
discuss opioids and monoamines. We aim to
explain the importance of central sensitization
and the dialogue of the spinal circuits with the
brain descending modulatory controls before
discussing a mechanism-based effectiveness of
antidepressants in pain therapy and their
potential to modulate the descending controls.
Emphasizing the roles of conditioned pain
modulation and its animal’s equivalent, diffuse
noxious inhibitory controls, we discuss these
unique descending modulations as a potential
tool for understanding mechanisms in patients
suffering from pain. Mechanism-based therapy
is the key to picking the correct treatments and
recent clinical studies using sensory symptoms
of patients as surrogates for underlying mecha-
nisms can be used to subgroup patients and
reveal actions of drugs that may be lost when
studying heterogenous groups of patients. Key
advances in the understanding of basic pain
principles will impact our thinking about ther-
apy targets. The complexity of pain syndromes
will require tailored pharmacological drugs,
often in combination or through drugs with
more than one action, and often psychother-
apy, to fully control pain.
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OVERVIEW OF PAIN PROCESSING
Organisms need to process incoming sensory
information and then respond to the external
world. Consequently, pain alters and overlaps
with other CNS functions such as those con-
cerned with mood and responses to the outside
world. All organisms need to sense their envi-
ronment and so our peripheral pain receptors
evolved from sensors seen in primitive crea-
tures. Organisms need to learn about sensory
stimuli and so centrally, the ability of spinal
neurones to become sensitized by repeated
stimuli is believed to be a part of associative
learning. Thus, the ancient origins of pain and
its widespread effects on CNS processes are
responsible for the challenges of controlling
pain and the misery it brings.
The future of pain control will involve novel
agents and a better use of existing therapies,
including steps towards predicting patient
responses based on improving our knowledge of
pain and its modulation. We are off to a solid
start in terms of success in dealing with the
challenges since translation from basic science
to patients, and vice versa, are becoming more
prevalent and connected. Parallel rodent neu-
ronal and human psychophysical studies can
inform on peripheral and central mechanisms
in experimental pain and so drug development
will find an easier and more predictive transi-
tion from experimental drugs to phase I studies
[49, 61]. Differentiation of the modulation of
on-going and evoked pains in rodent models
[33] has been achieved and this separation has a
bearing on responses to analgesics in neuro-
pathic patients [18]. In this account, we high-
light how anti-NGF and anti-CGRP antibodies
are reaching the patient, the effect of tapenta-
dol and the rationale for selective sodium
channel blockers, which are currently being
tested in patients [71].
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
DIFFERENT TYPES OF PAIN
A key issue is defining the receptors and chan-
nels involved in pain transmission and modu-
lation, both of which change following
pathophysiological events, such as those that
occur in patients with neuropathic and/or
inflammatory pain. Low back pain and cancer
pain can be a combination of the two, and are
thus mixed pains. Indeed, there are about 40%
of cancer patients with neuropathic pains and
similar numbers with neuropathic elements to
low back pain; the neuropathic components in
pain states can be teased out by questionnaires
and assessment of the sensory symptoms [13].
This is an important issue since treatments
aimed at the peripheral pain mechanisms have
to distinguish these two main types of pain.
Pain from tissue damage (inflammatory pains)
will respond to the NSAIDs and steroids,
whereas neuropathic pain (resulting from a
lesion or disease of sensory nerves) will respond
to drugs that target the altered ion channels
within the nerves. Thus, peripherally targeted
treatments must reflect the type of pain
mechanism.
We have managed to characterize many of
the pain sensors in the body. Nociceptors have a
polymodal nature so heat and cold sensors have
been found as well as a large number of recep-
tors that respond to chemical stimuli. A family
of particular sodium channels, some selective to
pain signaling, have been isolated [29]. The
peripheral mechanisms of the broad types of
pain are very different and so treatments are
linked to the pain type. Examples would be the
use of the NSAIDs and steroids for the afore-
mentioned inflammatory pains, but the need
for drugs acting on ion channels for neuro-
pathic pains where the lesion or disease of a
nerve leads to disordered electrical events.
However, on arrival within the central nervous
system, the signaling and controlling systems
appear to use common mechanisms, so that
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opioids, ketamine, and agents acting on the
monoamine systems have broader spectrums of
activity. Furthermore, the underlying mecha-
nisms of some manifestations of pain are more
likely to be central than peripheral, and here
both fibromyalgia and irritable bowel syndrome
are best explained by problems with brain con-
trol systems [53, 55]. The periphery provides the
basic information but each patient builds up
their own pain experience based on context,
memory, emotions, and social/other issues. The
outcome is subject to the incoming pain mes-
sages being modified and altered by the CNS,
both up and down. Thus, we should never be
surprised by any disconnect between the extent
of peripheral damage and the pain score.
PERIPHERAL EVENTS
THAT GENERATE NOCICEPTIVE
PAIN
Many pains start in the periphery where pain
sensors are likely to be continually activated
when tissue is damaged. Chemicals are released
including the prostanoids, bradykinin, CGRP,
and ATP, as well as many chemokines. The
problem is that, at present, only steroids and
cyclooxygenase inhibitors are able to modulate
these events with a ceiling on efficacy since they
will only modulate some of the chemical
mediators. Hopes for drugs that block the
receptors for ATP are high, and here the P2X3
receptor is a key target [9]. NGF is a key target
for inflammatory pains but there were problems
with initial therapies and their side effects.
Anti-NGF Therapies
NGF is a key molecule for the sensitization of
primary afferent nociceptors associated with tis-
sue inflammation. It acts via neurotrophic tyr-
osine kinase receptor A (TrkA), as well as via p75
neurotrophin receptor (p75NTR) and levels of
NGF increase in inflamed tissue. The molecule
has a number of direct and indirect (through
Mast cells and autonomic actions) effects to
enhance pain signaling. Preclinical data revealed
that neutralization of endogenous NGF prevents
inflammatory hyperalgesia [35, 45, 56, 60]. NGF
causes acute pain in humans but the NGF-TrkA
complexes are also retrogradely transported by
sensory fibers to the cell bodies, resulting in a
number of genomic actions that increase the
sensitivity of pain fibers. In addition to increased
ion channel functions, it causes the release of
substance P and CGRP at both peripheral and
central levels, and therefore contributing to
sensitization [60]. Hence, several studies illus-
trated the importance of NGF and/or CGRP
sequestration strategies in the variety of pain
states where tissue is damaged.
Among several agents developed to coun-
teract the NGF-mediated sensitization, particu-
lar attention should be drawn to monoclonal
antibodies like tanezumab, fulranumab, and
fasinumab. Several clinical trials revealed a
long-lasting (several weeks after a single injec-
tion) pronounced efficacy of tanezumab in the
management of osteoarthritic, chronic low
back, diabetic peripheral neuropathic, and
cancer-induced bone pains [32, 39, 62].
The major obstacle linked to the use of
anti-NGF antibodies that arose from clinical tri-
als was their osteonecrotic activity, often leading
to premature joint replacement. Recent trials
have adjusted the dose of tanezumab used, and
identified an interaction with other pharma-
cotherapies often used to manage inflammatory
conditions. Tanezumab monotherapy does not
elevate the risk of total joint replacements,
however if coadministered with NSAIDs, the risk
is notably manifested [59]. Also, there was a
minimal incremental benefit of high doses of
tanezumab high (10–20 mg) versus low (2–5 mg)
doses, further restricting side effects [12, 24].
Finally, anti-NGF antibodies do not appear to
have cardiovascular or gastrointestinal safety
liabilities ofNSAIDs, aswell as undesirable effects
of centrally acting analgesics such as opioids.
Anti-CGRP Agents in Headache
CGRP is a peptide found in many C-fibers and
released at both their central and peripheral
terminals. The latter action is a key event in the
production of migraine where the peptide is
likely to have both pain generating and vascular
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actions in dura and scalp [27]. Antibodies to
CGRP have been developed and been proven
effective, and it is hoped that these agents will
become alternatives to the triptans [46]. In
general, monoclonal antibodies are tar-
get-specific, which limits off-target toxicities
common to most small molecules. Their actions
are prolonged, which leads to less frequent
dosing of about once a month or less. Their long
half-life may lead to these molecules being used
for migraine prevention and CGRP attenuation
has potential use in other inflammatory pain
conditions.
PERIPHERAL EVENTS
THAT GENERATE NEUROPATHIC
PAIN
Ion Channels
Critical changes in ion channels, in particular
sodium channels, arise after nerve injury,
thought to produce abnormal peripheral trans-
mission to the spinal cord and we have proof of
concept since mutations in some of these
peripheral sensors and channels cause human
familial pain disorders [19]. The description of
certain sodium channels, namely Nav 1.7 and
1.8, which are preferentially found in small
fibers, lead to the possibility that their blockers
could be novel analgesics with pain-selective
actions, unlike present drugs such as lidocaine,
which also blocks large fibers. Indeed, there are
a number of gain-of-function of 1.7 mutations
that lead to pain in the absence of injury and a
loss of function mutation that renders the sub-
jects analgesic [10, 20]. This proof of concept
supports the idea that selective pain-related
sodium channel blockers could become orally
effective local anesthetic-like drugs [43] since
their selective roles in pain would not require
local administration and clinical studies with
NaV1.7 blockers are on-going [71].
These drugs could have broad efficacy that
includes inflammatory pains, where peripheral
sensitization will also lead to altered action
potential transmission. At present, we have
drugs such as carbamazepine that work to
subdue abnormal sodium channel function.
Potassium channels provide another interesting
target since these inhibitory channels are
down-regulated after nerve injury, but at pre-
sent we lack drugs that act to open them [66].
Further, new analgesics could include drugs
that target our sensors for heat, cold, and irri-
tants such as the TRP family of channels. These
are already pain-control targets since capsaicin
is an agonist at TRPV1. A low dose desensitizes
the channel whilst a high dose activates—it is
the human heat pain sensor—but then causes
the fine pain fibers to pull back from the area of
application, producing prolonged pain relief
[48]. TRPM8 is our cold sensor, responding to
menthol and this channel could be a useful
target in patients with cold hypersensitivity
such as those receiving cancer chemotherapy
[25, 51]. TRPA1 is an irritant sensor and a
gain-of-function mutation leads to a pain syn-
drome in humans, validating the channel as a
target [37].
Botulinum Toxin
Botulinum toxin has been used to control pain
in migraine and in patients with peripheral
neuropathy. As a paralytic agent, the drug
blocks transmitter release at the neuromuscular
junction, but this action can be harnessed to
control pain. In headache, the local adminis-
tration to sensory nerve terminals is thought to
block the release of CGRP as well as the inser-
tion of certain pain sensors into the membrane
of the nociceptors [52]. In neuropathy, the
authors concluded that the toxin may be
transported to the central terminals of the pain
fibers where it could block central transmitter
release [2].
SPINAL CORD MECHANISMS
OF PAIN
Whatever the cause of pain in the body, the
next key stage in communication between
peripheral nerves and CNS neurones is the
release of transmitter into the spinal cord. Cal-
cium channels are required for transmitter
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release and so control neuronal activity of
spinal neurones. Calcium channel levels and
function are altered in different pain states. In
particular, in both inflammatory and neuro-
pathic pains, there are increases in their func-
tion, and in the latter the alpha-2 delta subunit
is highly upregulated [15, 50]. This is the target
for the drugs gabapentin and pregabalin, which
appear to prevent the correct movement of the
channels to the membrane [7], and so act to
alter transmitter release through mechanisms
brought into play by pathophysiological events.
These drugs are active in certain physiopatho-
logical states (which may be generated periph-
erally by neuropathic mechanisms or intense
stimuli), but also in disorders of central pro-
cessing such as fibromyalgia, where they alter
glutamate signaling in the brain [30]. Both
preclinically and also in patients, the alpha-2
delta ligands appear to act preferentially on
evoked hypersensitivities and not on-going
pain, forming a basis for differentiation of
patients who might respond to them [50].
Central Sensitization
In the spinal cord, activation of the
N-methyl-D-aspartate (NMDA) receptor is pro-
duced by the repeated release of peptides and
glutamate from peripheral nerves. These actions
of glutamate at the NMDA receptor in persistent
pain states, acting alongside other systems,
produce hypersensitivity of spinal sensory neu-
rones. Consequences of this are wind-up,
long-term potentiation (LTP) and central sensi-
tization. This leads to both an increase in the
pain sensation and the receptive field size of the
spinal neurones [21]. This spinal hypersensitiv-
ity is the most plausible explanation for allo-
dynias since the deep dorsal horn neurones
subject to wind-up receive both low and high
threshold inputs. The NMDA receptor is a key
target for controlling pain. Ketamine blocks the
NMDA receptor complex at sub-anesthetic
doses but with side effects, and there is a
potential for drugs with better profiles through
NMDA receptor sub-type selective agents. The
other receptors for glutamate are unlikely to be
viable targets since glutamate is the main CNS
excitatory transmitter. Tissue and nerve trauma
causes abnormal impulse propagation towards
the spinal cord and marked changes in calcium
channels causing them to release more trans-
mitter, thereby favoring central spinal hyper-
sensitivity. Here, the relation between the
extent of peripheral activity and central conse-
quences diverge and shift towards central
hypersensitivity. It has been difficult to directly
modulate central sensitization, but certain
drugs can be useful: directly as with ketamine,
and indirectly as with opioids and gabapenti-
noids [58, 67]. Central sensitization has been
observed in many patient groups, ranging from
neuropathy to osteoarthritis including
fibromyalgia [54]. Given that the originating
events in these very different pains can be
clearly peripheral or more likely central, such as
in fibromyalgia, it becomes clear that altered
processing and sensitization can be observed at
many CNS sites.
Altered Pain Transmission in the Brain
Increased activity within spinal circuits pro-
duced by peripheral activity, whether arising
from tissue or nerve damage, is the rationale for
the use of regional blocks since in most cases,
the spinal events are driven by peripheral
inputs. Increased spinal neuronal activity will in
turn trigger ascending activity to the brain.
There are two parallel pathways; firstly,
ascending activity to the thalamus and the
cortex, the sensory components of pain, allow
us to locate and describe the intensity of the
pain. Equally important are the pathways to the
midbrain and brainstem, where the activity
contacts and disrupts the limbic brain, areas
such as the amygdala, and generates the com-
mon comorbidities that follow pain such as
depression, fear, sleep problems, and anxiety.
The brain processes and signals, in a dynamic
fashion, the sensory and affective components
of pain as well as the salience and aversive
aspects of pain through connections between
various areas that include insula, prefrontal and
cingulate cortices, as well as the somatosensory
cortex [38]. The ascending pain messages from
the cord that input these various brain regions
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also contact descending control pathways that
run from the brainstem back to the spinal cord.
These monoamine and opioid projections can
be inhibitory or excitatory, so that cognitive
and emotional events are able to switch pain on
or off.
Central Inhibitory Mechanisms
Blocking the generation of excitability is one
approach, and this can be achieved by target-
ing the periphery or the spinal cord, but
increasing inhibitions may also provide con-
trol of pain. Opioids work at spinal levels by
pre- and post-synaptic mechanisms and the
spinal application of morphine in animals
rapidly lead to the human epidural route in
patients. Systemic opioids both increase
descending inhibitions and reduce descending
facilitations by CNS actions. All of these
mechanisms are altered as pain shifts from
acute to chronic. Opioids can be useful in pain
control, although this is less clear for chronic
non-malignant pain where there are issues
with side effects, abuse potential, and overdose
risk from the opioid load and potential para-
doxical hyperalgesia as the inhibited spinal
neuronal systems compensate [64]. An advance
has been tapentadol, which is a mu opioid with
noradrenaline reuptake inhibition, a dual-ac-
tion molecule, with key spinal actions [8]. The
latter action targets and enhances descending
inhibitions and so opioid side effects are
reduced. All presently used opioids act at the
mu opioid receptor but can differ in potency,
pharmacokinetics, and route of administra-
tion. Recently, after many decades of attempts
to produce drugs acting on the other opioid
receptors, agonists at the NOP receptor have
gone into patients [42].
A severe loss of spinal GABA-mediated inhi-
bitions is reported within the spinal cord after
peripheral nerve injury, which compound the
gain of excitation. The widespread nature of the
roles of GABA in the brain means that therapies
aimed at restoring its normal inhibitions are not
currently feasible. Altering the function of the
chloride channel that GABA operates is being
attempted [22].
Pathways from the Brain to the Spinal
Cord that Alter Pain
Abnormal signaling from the spinal cord alters
pain processing in the brain. Pathways from the
brain can in turn alter spinal sensory processing
[4]. These projections originate from the mid-
brain and brainstem in predominantly mono-
amine systems (noradrenaline and 5HT). The
actions of anti-depressant drugs in pain there-
fore link to these systems. These pharmacolog-
ical circuits also play major roles in the
generation and control of emotions such as
mood, fear, and anxiety as well as in ther-
moregulation and the sleep cycle. Pain inputs
into these areas will alter descending controls
and also form a basis for pain-induced co-mor-
bidities. Early work in this field focused on
descending inhibitions, which are now known
to be predominantly noradrenergic acting
through the alpha-2 adrenoceptor [31]. A
recruitment of descending inhibitions underlies
placebo analgesia and a failure of descending
inhibitions has been reported in many patient
groups with diverse types of pain [68]. However,
pain could equally be increased by enhanced
descending facilitations through the 5HT3
receptor [57, 65]. These excitatory influences
from the brain will act to favor the development
and maintenance of central sensitization in the
spinal cord [14]. Part of the substrates for these
bidirectional controls are ON and OFF cells
found in brainstem nuclei [26]. There appear to
be altered descending excitatory controls in
patients with severe pain from osteoarthritis
[28]. In animals, there is a loss of descending
noradrenaline controls after nerve injury and
correspondingly, animals with nerve injury that
have activated their descending inhibitory
noradrenergic systems are protected against the
pain and recovery from surgical pain is
enhanced when the same systems operate [17].
In general, painful inputs into the limbic
brain and the resultant descending controls link
emotional states and the levels of pain per-
ceived, and could be one of the ways by which
higher functions such as coping and catastro-
phizing can modulate sensory components of
pain at the level of the first relays in the spinal
cord. The levels of midbrain-generated
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modulation, both positive and negative, may be
a key factor in individual variations in pain, the
potential target for non-pharmacological ther-
apies and contribute to some ‘‘dysfunctional’’
pain states such as fibromyalgia. Here, a ‘‘nor-
mal’’ peripheral input could be enhanced if the
descending systems are abnormal and so
enhance excitability of the spinal cord through
central events [53, 63]. Diffuse pains may have
their origins in disordered central pain modu-
lation. Animal studies reveal that altered
descending controls are important in the
maintenance of persistent inflammatory and
neuropathic pains [4].
Gauging Descending Inhibitions
in Patients
The balance shifts towards descending facilita-
tion in persistent pains and importantly the
extent of loss of descending inhibitions in
patients can be gauged. The finding that one
pain could inhibit another through descending
controls formed the basis for diffuse noxious
inhibitory controls (DNIC) [41] and its human
counterpart, conditioned pain modulation
(CPM) [68], a descending inhibition that is lost
in patients with brainstem lesions and spinal
sections [11].
Recent studies reveal that DNIC use a
descending noradrenaline and alpha-2 adreno-
ceptor-mediated pathway from the brain to the
spinal cord [5]. Sham surgery produces no
change in DNIC and no pain phenotype corre-
sponding to reduced CPM being a risk factor for
persistent pain after surgery [69]. After periph-
eral neuropathy, DNIC is lost, yet can be
restored by drugs that enhance noradrenalin
levels and also by blocking the 5HT3-mediated
descending facilitations [5]. In patients, reduced
CPM is seen in many pain states, including
neuropathy, osteoarthritis, headache, CRPS,
fibromyalgia, and others [1, 40, 70]. CPM can be
quantified by one pain versus another, often
heat versus cold but as with DNIC, the modality
of the conditioning stimulus only has to be
noxious and the wide dynamic range of the
neurones in animals subject to DNIC means
that the conditioned response can be noxious
or innocuous [36]. Importantly, CPM can be
restored in patients with peripheral neuropathic
pain by the MOR-NRI drug tapentadol and a
reduced CPM is predictive of efficacy of the
SNRI duloxetine, suggestive of a loss of key
noradrenaline signaling in patients akin to that
seen with DNIC in animals [44, 70]. Both DNIC
and CPM are dynamic—CPM can be present
early in a pain condition but lost later such as
with CRPS and alters over the course of head-
aches [47].
On-Going and Evoked Pains
CPM allows for the quantification of descend-
ing inhibitions and so is a key step towards
precision medicine. An overwhelming question
is whether it is the spontaneous or the stimu-
lus-evoked component of pain that is the
greater problem for patients who are simply
asked to rate their pain on a VAS score. Differ-
entiating the two pain events, for example
neuropathic spontaneous pain and inflamma-
tory tonic pain from evoked, particularly
mechanical hypersensitivity, is an on-going
research goal both pre-clinically and clinically.
Despite its terminology, spontaneous pain not
only refers to the intrinsic firing of neurons
active in pain-signaling pathways, but may
rather—in the case of neuropathy for example—
refer to deafferentation-induced spontaneous
discharge in CNS neurons. The sensitization of
such pain signaling neurons may then be
responsible for on-going chronic pain. Stimu-
lus-evoked hypersensitivity meanwhile refers to
an enhanced neuronal, and therefore pain,
response to an innocuous or noxious insult at
the periphery.
The presence of spontaneous pain is a com-
mon complaint amongst chronic pain patients,
for example those with a neuropathy [3]. An
increased sensitivity to evoked stimuli is also
present in such patients. Importantly, hyperal-
gesia can be pharmacologically treated in the
absence of the relief of on-going pain [23] and so
it is likely that the underlying mechanisms gov-
erning on-going versus evoked pain are distinct
and thus should be treated clinically as separate
components of the pain state. It is well accepted
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that translating mechanisms in animal models
can guide potential treatments in the patient
domain. While detecting and mechanistically
evaluating spontaneous pain pre-clinically was
viewed as a complicated task, an insightful study
by Frank Porreca and colleagues used condi-
tioned place preference (CPP) to not only detect
tonic pain in neuropathic rats but also to deter-
mine the efficacy of specific analgesic relief [34].
Their study provided evidence for a tonic pain
state in animals that had undergone spinal nerve
ligation (SNL) surgery, while the presence of a
spinal cord lesion similarly coincides with the
expression of spontaneous pain, with CPP this
time revealing that clonidine or motor cortex
stimulation was able to unmask a tonic aversive
state [16]. Further studies reveal that certain
brain areas such as the anterior cingulate cortex
may contribute more to the longing aversive
state rather than modulating evoked responses
and importantly such studies impact the assess-
ment of analgesic therapeutic potential on these
different responses [33].
TARGETING PAIN MECHANISMS
IN PATIENTS
Whilst awaiting new agents, our understanding
of mechanisms for pain and its treatments
allows for a rationale for all approaches to pain
control. These could range from regional blocks
to restoration of normal central modulation
with drugs to cognitive behavioral approaches.
Indeed, even the descending controls, embed-
ded deep in the brain, are altered by peripheral
inputs and so could be altered by peripheral and
spinal interventions.
But who will respond to each particular
treatment? NNTs for many pain drugs are quite
high but trials have been based on etiology and
so presume homogeneity, whereas the patients
may have differing mechanisms and sensory
profiles. Mechanism-based therapy is a laudable
concept but unlikely to be helpful since how
could mechanisms be identified in most
patients? A brilliant variant on this would be to
use the sensory phenotype of the patient as a
surrogate reflection of underlying pain
mechanisms. Using the sodium channel blocker
oxcarbazepine, it was revealed that those
patients with ‘‘irritable nociceptors’’, i.e., having
evoked hypersensitivity rather than on-going
pain, responded to the drug, an effect that was
lost in the whole group analysis [18]. Subtypes
of patients with neuropathic pain, fibromyalgia
and post-surgical pain can be formally distin-
guished. Analysis of patients with neuropathic
pain has revealed three clusters of patients:
Cluster 1—those with sensory loss; Cluster 2—
those with thermal hyperalgesia; Cluster 3—
those with mechanical hyperalgesia. In the near
future, we will know if these subtypes have
differential responses to different drugs if strat-
ified trials can be conducted, but there are
already hints of differential sensitivities to
treatments. Cluster 1 patients responded to oral
opioids and not well to Na channel block,
whereas Cluster 2 patients did respond to this
drug and also to BoTox. Cluster 3 had greater
efficacy of pregabalin and topical or IV lido-
caine [6]. There is also the use of CPM, as dis-
cussed previously, to inform on impaired
descending inhibitions and so predict respon-
ders to SNRIs and sensitivity to tapentadol.
Other studies, at present limited to neuropathic
pain, reveal heterogeneous responses to drugs
in different subgroups of patients [13], and this
needs to be extended to nociceptive pain
patients and those with fibromyalgia.
There is considerable hope for the future.
However, the use of both CPM and/or quanti-
tative sensory testing are not appropriate for
routine clinical practice, so if there is a relation
between particular sensory profiles of patients
and particular pharmacological agents, simple
tests could be developed. Patients should be
able to distinguish on-going from evoked pains
during the taking of a history and could be
asked if their pains were predominantly thermal
or mechanically evoked, so delineating the
clusters described above [6]. Maybe patients
could be asked if one pain could inhibit their
pain—bite your thumb? This could represent a
simple test of CPM.
We have a lot further to go but the union of
informed and thoughtful preclinical science
and clinical medicine will lead us onwards.
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